We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Procaps Group SA | NASDAQ:PROC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -4.76% | 1.60 | 1.43 | 1.75 | 1.7584 | 1.5001 | 1.69 | 65,075 | 01:00:00 |
Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023.
The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results.
To access the call, please use the following information:
Date:
Tuesday, September 5, 2023
Time:
11:00 a.m. ET
Webcast:
Click here to access
Toll Free dial-in number:
1-844-204-8586
Toll/International dial-in number:
1-412-317-6346
Conference ID:
Procaps Group
The conference call will be broadcast live and available for replay at https://bit.ly/45sB21M and via the investor relations section of Procaps’ website here.
A telephone replay will be available approximately two hours after the call and will run through September 12, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 1873850.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230831666715/en/
Investor Contact: Melissa Angelini ir@procapsgroup.com investor.procapsgroup.com
1 Year Procaps Chart |
1 Month Procaps Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions